- Home
- CATX vs BWAY Comparison
CATX vs BWAY Comparison
Compare CATX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- BWAY
- Stock Information
- Founded
- CATX 1983
- BWAY 2003
- Country
- CATX United States
- BWAY Israel
- Employees
- CATX N/A
- BWAY N/A
- Industry
- CATX Medical/Dental Instruments
- BWAY Medical/Dental Instruments
- Sector
- CATX Health Care
- BWAY Health Care
- Exchange
- CATX Nasdaq
- BWAY Nasdaq
- Market Cap
- CATX 239.0M
- BWAY 280.7M
- IPO Year
- CATX N/A
- BWAY 2019
- Fundamental
- Price
- CATX $2.73
- BWAY $16.81
- Analyst Decision
- CATX Strong Buy
- BWAY Strong Buy
- Analyst Count
- CATX 10
- BWAY 2
- Target Price
- CATX $12.30
- BWAY $18.00
- AVG Volume (30 Days)
- CATX 1.7M
- BWAY 61.5K
- Earning Date
- CATX 11-10-2025
- BWAY 11-11-2025
- Dividend Yield
- CATX N/A
- BWAY N/A
- EPS Growth
- CATX N/A
- BWAY 679.98
- EPS
- CATX N/A
- BWAY 0.11
- Revenue
- CATX $1,235,000.00
- BWAY $46,084,000.00
- Revenue This Year
- CATX N/A
- BWAY $335.63
- Revenue Next Year
- CATX N/A
- BWAY $22.10
- P/E Ratio
- CATX N/A
- BWAY $60.12
- Revenue Growth
- CATX N/A
- BWAY 26.50
- 52 Week Low
- CATX $1.60
- BWAY $7.84
- 52 Week High
- CATX $12.90
- BWAY $17.49
- Technical
- Relative Strength Index (RSI)
- CATX 35.35
- BWAY 63.31
- Support Level
- CATX $2.85
- BWAY $16.44
- Resistance Level
- CATX $3.15
- BWAY $17.49
- Average True Range (ATR)
- CATX 0.47
- BWAY 0.75
- MACD
- CATX -0.17
- BWAY 0.10
- Stochastic Oscillator
- CATX 0.75
- BWAY 76.70
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.